Print

Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB)'s Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma, Rabin Medical Center (Beilinson Hospital) Study  
2/11/2009 7:33:47 AM

LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on Tuesday.
//-->